CareDx, Brisbane, Calif, and Veracyte, South San Francisco, Calif, have formed an agreement through which CareDx will become the exclusive worldwide commercialization partner for solid organ transplant rejection tests on the nCounter Flex analysis system, Veracyte’s diagnostic platform.
Bonnie Anderson, Veracyte.
CareDx had previously announced plans to develop HistoMap, a gene expression profiling solution to identify allograft rejection in transplant biopsy tissue. HistoMap will run on the nCounter Flex analysis system and will be developed using the human organ transplant panel from the Banff Foundation for Allograft Pathology. CareDx will be responsible for global commercialization of HistoMap.
Peter Maag, CareDx.
“With HistoMap added to our strong KidneyCare and HeartCare offerings, we will ensure that biopsies performed are reproducibly clinically relevant. This fits well into our approach of multimodality testing and patient stratification,” says Peter Maag, chairman and chief executive officer of CareDx. “We are glad to partner with Veracyte to make these solutions available for transplant patients.”
“We are pleased to partner with CareDx, a leader in transplant solutions with a track record of bringing innovative tools to clinical care,” says Bonnie Anderson, Veracyte’s chairman and chief executive officer.
